tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Rachel Vatnsdal, 6 are a SELL (12.5%), 21 are a HOLD (43.75%), 21 are a BUY (43.75%).
Analyst Rachel Vatnsdal, currently employed at JPMORGAN, carries an average stock price target met ratio of 55.77% that have a potential upside of 20.42% achieved within 89 days.
Rachel Vatnsdal’s has documented 105 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RGEN, Repligen at 21-Feb-2025.
Analyst best performing recommendations are on TXG (10X GENOMICS).
The best stock recommendation documented was for TXG (10X GENOMICS) at 7/18/2024. The price target of $20 was fulfilled within 8 days with a profit of $3.44 (20.77%) receiving and performance score of 25.97.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$0.65
$0.51 (364.29%)
$3.35
1 years 9 months 13 days ago
(18-May-2023)
2/2 (100%)
$0.06 (10.17%)
10
Buy
$1.25
$1.2 (2400.00%)
$19
1 years 9 months 22 days ago
(10-May-2023)
3/4 (75%)
$2.13 (47.39%)
21
Buy
$5
$4.86 (3471.43%)
$30
1 years 11 months 15 days ago
(16-Mar-2023)
7/10 (70%)
$3.68 (278.79%)
819
Hold
$2
$1.86 (1328.57%)
$2.5
2 years 2 months ago
(03-Jan-2023)
1/2 (50%)
$0.55 (37.93%)
2
Hold
2 years 3 months 22 days ago
(09-Nov-2022)
1/2 (50%)
$7.57 (43.43%)
391
Which stock is Rachel Vatnsdal is most bullish on?
Which stock is Rachel Vatnsdal is most reserved on?
What Year was the first public recommendation made by Rachel Vatnsdal?
